Applying ADAURA in Practice: Implications For Early Stage EGFRM NSCLC
| Overview / Abstract: |
This educational initiative is targeted to medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists and molecular pathologists who are involved in diagnosis of early stage NSCLC that is surgically resectable with curative intent. In addition to examining the latest ADAURA trial data and the potential utility of adjuvant osimertinib in stage IB-IIIA EGFRm NSCLC, the practice-changing implications of these results will also be explored from a variety of perspectives with three different specialties. There will be interactive discussion regarding practical strategies to ensure early biomarker testing to such that patients with EGFR-mutant disease can potentially benefit from adjuvant targeted therapies. |
|
Expiration |
Apr 01, 2022 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.0 |
|
Accreditation |
ACCME |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Lecia V. Sequist, MD, MPH (Moderator) Charu Aggarwal, MD, MPH Dara Aisner, MD, PhD David Tom Cooke, MD, FACS |
|
Activity Specialities / Related Topics |
Pulmonary Medicine / COPD, Oncology / Cancer / Radiation Therapy |
|
Sponsors / Supporters / Grant Providers |
Supported by an independent educational grant from AstraZeneca. |
|
Keywords / Search Terms |
CE Concepts medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, molecular pathologists, early stage NSCLC, NSCLC, ADAURA, stage IB-IIIA EGFRm, EGFR-mutant, EGFR Free CE CME Live CE CME |
|